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Background: Rheumatoid arthritis (RA) is a chronic inflammatory arthritis, with significant impact on quality of life
and functional status. Whilst biologic disease modifying anti-rheumatic drugs (bDMARD) such as tumour necrosis
factor-inhibitor (TNFi) agents have revolutionised outcomes in RA, early diagnosis with immediate conventional
therapy, titrated in a treat to target approach is also associated with high remission rates. The main aim of the
VEDERA study (Very Early versus Delayed Etanercept in Rheumatoid Arthritis) is to assess the depth of remission,
sustainability of remission and immunological normalisation induced by very early TNFi with etanercept (ETN) or
standard of care +/- delayed ETN.
Methods/Design: VEDERA is a pragmatic, phase IV single-centre open-label randomised superiority trial of 120
patients with early, treatment-naive RA. Patients will be randomised 1:1 to first-line ETN and methotrexate (MTX) or
MTX with additional synthetic disease modifying anti-rheumatic drugs (sDMARDs) according to a treat to target
(TT) protocol with further step up to ETN and MTX after 24 weeks if remission is not achieved. Participants will
have regular disease activity assessments and imaging evaluation including musculoskeletal ultrasound and MRI.
The main objective of this study is to assess the proportion of patients with early RA that achieve clinical remission
at 48 weeks, following either treatment strategy. In addition, the participants are invited to take part in a cardio-vascular
sub-study (Coronary Artery Disease in RA, CADERA), which aims to identify the incidence of cardiovascular
abnormalities in early RA.
Discussion: The hypothesis underlining this study is that very early treatment with first-line ETN increases the
proportion of patients with rheumatoid arthritis achieving clinical remission, in comparison to conventional therapy.
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Rheumatoid arthritis (RA) is a chronic inflammatory
arthritis, characterised by symmetrical, often erosive, in-
flammatory polyarthritis of the small and medium sized
joints, which can lead to significant disability and de-
creased function [1]. The overall burden of disease how-
ever extends beyond the joints to include wide-ranging
extra-articular manifestations and comorbidities [2].
The fundamental paradigm in the management of RA
is that early, effective suppression of synovitis by early
diagnosis and immediate initiation of disease modifying
anti rheumatic drug (DMARD) therapy is associated
with improved outcomes. Guidelines recommend syn-
thetic DMARD (sDMARD) as a first line therapy with
step-up to biological DMARD (bDMARD) treatment in
the presence of continued disease activity. Internation-
ally agreed guidelines recommend a treat to target (TT)
approach, a concept established for the management of
pathologies such as arterial hypertension and diabetes
[3]. In RA, TT implies frequent monitoring using a com-
posite disease activity measure such as the disease activ-
ity score-28 joint (DAS28) and escalation of therapy
according to a pre-defined target of remission or at least
low disease activity (LDA) [4, 5]. Tight control of disease
activity with intensive treatment, either step-up [6] or
parallel [7, 8] in early RA is associated with an improve-
ment in medium and long term outcomes.
The introduction of bDMARDs has provided highly ef-
fective therapy with which to achieve effective disease
control [9–11]. There are currently five licensed tumour-
necrosis factor-inhibitor (TNFi) therapies, the first
bDMARDs to be approved for use, of which etanercept
(ETN) is a recombinant TNF receptor fused to a human
Fc molecule forming a bivalent TNF binding agent. ETN
reduces inflammation, improves functional status and
quality of life and inhibits radiographic progression
[12, 13]. As with other TNFi, ETN is recommended
following MTX-inadequate response [14], and in the
UK after failure of at least two sDMARDs (of which
one should be MTX) [15].
Recent studies including COMET [16], ASPIRE [17]
and OPTIMA [18], suggest that TNFi therapy in the
early phase of the disease, prior to failure of sDMARDs,
offers improved rates of response and inhibition of
radiographic progression in comparison to sDMARD.
Sub-analysis of the COMET study shows that patients
receiving very early treatment with ETN and methotrex-
ate (within the first 4 months of disease) achieve greater
rates of remission than those with longer disease [19].
Furthermore, studies suggest that when commenced
early, TNFi may offer a greater depth of remission that
is more likely to be sustained after drug withdrawal [20].
In recent years, increasing consideration has been given
to the ‘window of opportunity’ concept: a phase in earlydisease in which it may be possible to alter the
pathogenic course of the disease [21]. However, not
all studies demonstrate the superiority of TNFi when
compared to TT regimen in early disease; in a group
of DMARD-naive early RA patients, no statistically
significant differences were found between patients
receiving MTX and intravenous steroids, followed by
TT regimen and combination therapy with MTX and
infliximab [22]. There is thus, continued debate on
how best to apply TNFi therapies in order to obtain
the maximal benefits to the patient whilst considering
socio- and health-economic costs. In addition, in-
creasing research is aimed at identifying predictors of
response. This includes use of TNFi within a TT
strategy [17, 18], and for remission [23].
An additional challenge is the assessment of thera-
peutic response. Whilst clinical scores such as DAS28
form the basis of evaluation, it is accepted that these
may be insensitive [24]; imaging modalities such as
power Doppler (PD) ultrasound (US) and dynamic mag-
netic resonance imaging (MRI) enable more accurate as-
sessment of inflammation as well as providing insights
into the pathobiology of disease [25].
Methods/Design
Aims and objectives
The main aim of the VEDERA study (Very Early versus
Delayed ETN in Rheumatoid Arthritis) is to evaluate
the depth of remission, sustainability of remission and
immunological normalisation induced by very early
TNFi or the current standard of care (with or without
delayed TNFi if required), in patients with early,
treatment-naive RA.
Research hypothesis
Very early treatment with first-line ETN increases the
proportion of patients with rheumatoid arthritis achiev-
ing clinical remission, in comparison to conventional
therapy.
Primary objective
The primary objective of this study is to assess the pro-
portion of patients with early, treatment-naive RA that
achieve clinical remission at 48 weeks following first-line
ETN and MTX (‘very early ETN’) or MTX with add-
itional sDMARDs and step up to ETN and MTX at 24
weeks, as required according to a TT protocol aiming
for remission (‘delayed ETN’).
Secondary objectives
 To assess the change in MRI synovitis between
baseline and 48 weeks following very early ETN or
MTX-TT regimen +/- delayed ETN.
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weeks 12, 24, 48 and 96 including:
✓ Disease activity score-44 joint (DAS44) remis-
sion (DAS44 < 1.6), simplified disease activity
index (SDAI), clinical disease activity index
(CDAI), European League Against Rheumatism
(EULAR) response criteria, American College of
Rheumatology (ACR) response criteria.
✓ Cumulative steroid dose.
 To evaluate patient-reported outcomes at weeks 12,
24, 48 and 96 including:
✓ Physical function, assessed by the Health
Assessment Questionnaire (HAQ), including
normalisation of HAQ.
✓ Quality of life scores assessed by RA Quality of
Life (RA-QoL) and Euro QoL Five Dimensions
(EQ-5D) questionnaires.
✓ Work instability, assessed by RA Work
Instability Score (RA-WIS) questionnaire.
 To evaluate imaging predictors of remission and
sustained remission using:
✓ High-resolution ultrasound (HRUS) at weeks
0, 12, 24 and 48 measuring grey scale (GS),
PD and presence or absence of erosions.
✓ Magnetic Resonance Imaging (MRI) at weeks
0, 12, 24 and 96 measuring synovitis and
erosion scores.
 To evaluate other radiographic outcomes including:
✓ Joint damage assessed by modified Sharp score
of X-rays of hands and feet at weeks 48 and 96.Exploratory objectives
 To investigate immunological abnormalities and
cellular/molecular predictors of response to the two
therapeutic strategies using:
✓ Blood, sampled at baseline and weeks 12, 24,
36, 48 and 96.
✓ Synovial tissue (optional), biopsied from a
target joint at baseline and 24 weeks; at 48
weeks for treatment arm 2 who have switched
to ETN and at time of flare.Study design
The VEDERA study is a phase IV single-centre open-label
randomised trial of 120 patients with early, treatment-
naive RA. Patients will be randomised 1:1 to first-line
ETN and MTX or MTX with additional sDMARDs and
step up to ETN and MTX after 24 weeks as required ac-
cording to a TT protocol aiming for remission.
The randomised trial duration is 48 weeks after
which ETN will be stopped and patients will continue
for a 48-week observational period during whichDMARDs will be used as per standard care, in ac-
cordance with national guidelines.
Patient eligibility
The target population are males and females, aged
between 18 and 80 years, fulfilling the 2010 American
College of Rheumatology/European League against
Rheumatism (ACR/EULAR) RA classification criteria,
who have not yet received DMARD therapy, with a
maximum symptom duration of 12 months. Other
criteria for inclusion are: patients with active RA at
baseline (clinical evidence of synovitis and DAS28-
ESR > 3.2) and positive anti-citrullinated peptide anti-
body (ACPA) or rheumatoid factor (RF) status. In the
absence of RF and ACPA antibodies, patients are eli-
gible for the study if they have evidence of power
Doppler, a good indicator of active inflammatory
pathology and predictor of structural damage. Power
Doppler grade ≥1 in at least 1 joint on hand ultra-
sound is required (Table 1).Recruitment
Participants will be recruited from the rheumatology
clinics based within Leeds Teaching Hospitals NHS
Trust. The recruitment period is expected to last up
to 36 months. All patients in the VEDERA study will
be invited to participate in CADERA, the cardiovas-
cular sub-study.Screening
Following written informed consent and prior to any
trial related procedures, participants will be registered
and undergo a screening assessment that should occur
no more than four weeks prior to the baseline assess-
ments, to determine eligibility for the study.Randomisation
Once eligibility is confirmed and all relevant procedures
have been completed, participants will be block rando-
mised 1:1 to one of the following two treatment groups
(Fig. 1): Treatment Arm 1 or ‘very early ETN’ will receive
ETN and MTX combination therapy administered
for a total duration of 48 weeks.
 Treatment Arm 2 or ‘delayed ETN’ will receive
initial MTX monotherapy with adoption of a TT
protocol (standard care involving monthly DAS28-
ESR assessment with escalation to combination
sDMARD therapy if not achieving LDA at, or
after, 8 weeks) and step-up to ETN and MTX at
24 weeks if failing to achieve clinical remission.
Table 1 Eligibility criteria for randomisation into VEDERA trial
Inclusion Criteria
• Male and female patients aged between 18 and 80 years.
• Diagnosis of rheumatoid arthritis (new 2010 ACR/EULAR RA classification criteria).
• Symptom onset within the preceding 12 months.
• Patients with active RA at baseline: clinical evidence of synovitis (or imaging-evidence of synovitis in cases of uncertainty/subclinical disease) in
hand and/or wrist joints evaluable by ultrasound and MRI, and DAS28-ESR > 3.2.
• Seropositivity for anti-citrullinated peptide antibody (ACPA) and/or rheumatoid factor. If ACPA and rheumatoid factor are both negative, presence
of power Doppler (grade 1 or higher) in at least 1 joint on hand ultrasound is required.
• DMARD-naive (with the exception of previous exposure to hydroxycholorquine for an indication other than RA).
• All male and female subjects biologically capable of having children must agree to use a reliable method of contraception for the duration of the
study and 24 weeks after the end of the study period. Acceptable methods of contraception are surgical sterilisation, oral, implantable or
injectable hormonal methods, intrauterine devices or barrier contraceptives.
Exclusion Criteria
• Previous treatment with DMARDs for the management of RA.
• Intramuscular or intra-articular (of non-target joint) corticosteroid within 28 days of the screening visit; intra-articular steroid of the chosen target
joint within 12 weeks of screening.
• Oral steroid of greater than 10mg prednisolone daily, or change in oral steroid dose within 28 days of study drug initiation at the baseline visit.
• Use (including use as required) of more than one NSAID, change in NSAID or change in dose of NSAID within 28 days of the baseline visit.
• Contraindications to MRI (e.g. pacemaker) or unable or unwilling to attend for all imaging assessments. In patients with previous penetrating
trauma to the eye, or patients at high risk of previous metal foreign body injury to the eye (e.g. welding), skull x-ray will be performed; these
patients may be included in the absence of residual metal fragments on x-ray.
• Pregnancy or breastfeeding.
• Other contraindications to TNFi as determined by local prescribing guidelines and physician discretion, including: active infection, open leg
ulcers, previously infected prosthetic joint (unless completely removed), septic arthritis in last year, HIV, Hepatitis B or Hepatitis C carriers,
previous malignancy within 10 years (except basal cell carcinoma), severe heart failure (New York Heart Association grade 3 or more), any
history of demyelinating disease, uncontrolled diabetes, pulmonary fibrosis, bronchiectasis, previous PUVA therapy (of >1000 Joules), history of TB or
evidence of latent TB on chest x-ray/TB testing (in the latter event, a patient may be included if treated with isoniazid and pyridoxine one month
before starting the study and for a further 6 months whilst on study treatments).
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Treatment arm one
For treatment arm one (Table 2), ETN will be adminis-
tered subcutaneously up to week 48 (except in the case
of intolerance or subject withdrawal) at a dose of 50 mg
weekly. MTX will be administered orally at a starting
dose of 15 mg weekly, increasing to 20mg and 25mg
weekly at weeks 4 and 8 respectively. Patients that are
clear non-responders or intolerant to ETN and/or MTX
will be managed according to physician discretion (with-
drawing these study treatments if appropriate).
Treatment arm two
In treatment arm two (Table 2), MTX will be adminis-
tered orally at a starting dose of 15 mg and will be in-
creased to 25mg weekly at 2 weeks. Subcutaneous MTX
may be administered if intolerance to oral MTX is ob-
served. If at weeks 8, 12, 16 or 20, the subject fails to
achieve LDA (defined as DAS28-ESR ≤ 3.2), sulfasalazine
(SSZ) and hydroxychloroquine (HCQ) will be added to
MTX. SSZ will be administered orally at a dose of 1g
twice daily (or at the maximum tolerated dose). HCQ
will be administered at a dose of 200mg daily. At 24
weeks, if a subject fails to achieve clinical remission,ETN will be added to MTX, and SSZ and HCQ will
be discontinued (if applicable).Treatment arms 1 and 2
Oral folic acid will be administered at a dose of 5mg
daily (except on the day of MTX) to subjects in both
treatment arms.
ETN will be discontinued in both arms at the primary
endpoint (48 weeks), with the exception of those pa-
tients who are eligible to continue according to local
prescribing guidelines (NICE guidelines) [15].
A single non-steroidal anti-inflammatory drug (NSAID)
is permitted providing the dose has been unchanged for at
least 28 days prior to study drug initiation at baseline. The
NSAID or NSAID dose may be changed during the time
course of the study if indicated.
Oral prednisolone is permitted at doses up to and in-
cluding 10mg prednisolone daily if the dose has been
stable for at least 28 days prior to study drug initiation
at baseline. The steroid dose may be reduced throughout
the study.
Intramuscular steroid may be administered as per the
study treatment protocol for each arm with all patients
Early, DMARD naive RA
Baseline
Treatment arm 1 
ETN+MTX
Baseline
Treatment arm 2
MTX
Week 8 onwards  
Add SSZ+HCQ if LDA is not achieved
Week 24
Start ETN/MTX if 
remission is not 
achieved
Week 24
Continue DMARD/TT 
regimen if remission 
Week 48
Stop ETN if applicable; continue treatment according to NICE guidelines
Week 96
End of study 
Fig. 1 Schematic of the trial design. DMARD disease modifying antirheumatic drugs, ETN etanercept, HCQ hydroxychloroquine, LDA low disease
activity, MTX methotrexate, NICE National Institute of Clinical Excellence, RA rheumatoid arthritis, SSZ sulfasalazine, TT treat to target
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less contraindicated or not tolerated) at baseline and at
the following time-points according to treatment arm
and disease activity:
 Week 12: both treatment arms, if DAS28-ESR > 3.2
 Week 24: treatment arm 1, if DAS28-ESR ≥ 2.6
(treatment arm 2 switch to ETN+/-MTX if
DAS28-ESR ≥ 2.6)
 Week 36:
✓ Treatment arm 1, if DAS28-ESR≥2.6
✓ Treatment arm 2, sDMARDs (MTX +/-SSZ
+/-HCQ), if DAS28-ESR≥2.6
✓ Treatment arm 2, switched to ETN+/-MTX, if
DAS28-ESR>3.2 Up to the primary endpoint (week 48), for a patient
with active disease who is judged by the physician to
be in need of rescue therapy, and for whom it is
considered to be unethical to wait until the 12,
24 and 36 week time points above, 120mg
methylprednisolone may be administered.
At and/or after the primary endpoint (week 48) intra-
muscular or intra-articular steroids are permitted accord-
ing to physician judgment, unless a clinical or imaging
assessment is scheduled within the following 6 weeks.
Alternative DMARDs, other than study treatments,
are permitted if clinically indicated in a subject judged
by the physician to be a non-responder (primary or sec-
ondary non-responder) or intolerant to ETN.
Table 2 Treatment arm scheme
Arm 1 Dosage form Dosage regimen Duration
ETN Subcutaneous 50mg weekly Up to week 48 unless non-response or intolerance.
MTX 2.5/10mg tablets
(or s.c.if oral not tolerated)
Weeks 0-4: 15 mg weeklyWeek 4: 20 mg
weeklyWeek 8 onwards: 25 mg weekly
For duration of study (unlessintolerance: aim for
maximumtolerated dose)
Folic Acid 5mg tablets 5mg, six days per week (not day of MTX) For duration of study (if receiving MTX)
Arm 2
MTX 2.5/10mg tablets
(or s.c. if oral not tolerated)
Weeks 0-2: 15 mg weeklyWeek 2 onwards:
25 mg weekly
For duration of study(unless intolerance,
aim formaximum tolerated dose)
Folic Acid 5mg tablets 5mg six days per week (not day of MTX) For duration of study (if receiving MTX)
SSZ 500 mg tablets 1 g twice a day At/after week 8 if not achieving low disease activity
(DAS28ESR > 3.2). Discontinuation if ETN is started
at week 24.
HCQ 200mg tablets 200mg tablets At/after week 8 if not achieving low disease activity
(DAS28ESR > 3.2). Discontinuation if ETN is started
at week 24.
ETN Subcutaneous 50mg weekly At week 24 to week 48 if not achieving remission
(DAS28ESR ≥ 2.6) Thereafter continuation will be
determined by physician judgement/according
to national guidelines.
ETN Etanercept, MTX Methotrexate, SSZ Sulfasalazine, HCQ Hydroxychloroquine
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Steroids are prohibited prior to week 48, with the excep-
tion of:
 Patients receiving ≤10mg prednisolone daily with a
stable dose for at least 28 days prior to study drug
initiation at baseline.
 Patients receiving prednisolone for an indication
other than arthritis, for example asthma or chronic
obstructive pulmonary disease (up to a maximum
total oral dose of 250mg, and a maximum duration
of 14 days).
 Intramuscular steroid as per the study treatment
protocol for each arm.
 120mg methylprednisolone administered as rescue
therapy (see above).
In the unavoidable instance of a subject receiving cor-
ticosteroid within a significant time window prior to a
clinical +/- imaging joint assessment the assessment will
not be performed. A significant time window is defined
as follows: intramuscular corticosteroid within 4 weeks
or oral prednisolone within 7 days of the assessment, ex-
cept patients on stable prednisolone ≤10mg.
At or after week 48, intramuscular or intra-articular
steroids are prohibited within 6 weeks of a scheduled
clinical or imaging assessment.
Other prohibited medications are any alkylating agents
(e.g. cyclophosphamide, chlorambucil), any experimental
drugs and immunisations with live vaccines.Study schedule
 Screening visit. All patients will undergo screening
within the 4 weeks prior to the baseline visit (see
section ‘Screening’ above).
 Baseline visit (week 0). This visit will be performed
to confirm eligibility for the study and for
randomisation and initiation of study treatment.
 Assessment and treatment visits. These visits will be
performed at weeks 4, 12 and every 12 weeks
thereafter, up to week 96, for both treatment arms.
 Additional visits (for treatment arm 2). The patients
in treatment arm 2 will also be monitored at week 8,
16 and 20 for safety and efficacy within a TT
protocol. In patients switching to ETN and MTX at
week 24 a follow up safety visit will be arranged 4
weeks following ETN commencement (i.e. week 28).
Methods of assessment
Clinical efficacy
Clinical efficacy and remission will be assessed by the
following measures, with joint examinations performed
by the same blinded assessor.
DAS44 and DAS28, based on the evaluation of four
variables: tender joint assessment (Ritchie Articular
Index, RAI, and 28 joint count respectively), number of
swollen joints (out of 44 and 28, respectively), erythro-
cyte sedimentation rate (ESR; mm/h) and patient’s global
assessment of arthritis, as assessed by a 100 mm visual
analogue scale (VAS). These will be performed at each
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using the following formulae: DAS28 = 0.56*sqrt
(tender28) + 0.28*sqrt(swollen28) + 0.70*ln(ESR) +
0.014*VAS; DAS 44 = 0.54*sqrt(RAI) + 0.065*(swollen
44) + 0.33*ln(ESR) + 0.0072*VAS. Remission thresholds
for DAS44 and DAS28 are <1.6 and <2.6 respectively [26].
CDAI is the sum of four variables: number of tender
and swollen joints (out of 28), the investigator’s global
assessment of disease activity and the patient’s global as-
sessment of arthritis assessed by VAS (cm). The thresh-
old for CDAI remission is <2.8 [27].
SDAI is the CDAI plus CRP (mg/dL). The threshold
for SDAI remission is <3.3 [28].
EULAR response criteria classify patients as good,
moderate or non-responders based on a combination of
the actual DAS and change from previous DAS [29].
ACR response measures 20 % (ACR20), 50 % (ACR50)
or 70 % (ACR70) improvement in tender and swollen
joint counts and in at least three of the following param-
eters: patient global assessment, physician global assess-
ment, pain, disability and acute phase reactant (ESR or
CRP) [30].
The physician global assessment of rheumatoid disease
activity should be completed before the patient’s global
assessment is received. The investigator will mark their
assessment on a 100 mm visual analogue scale (VAS):
the left end corresponds to none (0) and the right end to
extremely active (100).Patient-reported outcomes
Patient general health assessment and pain visual
analogue scales (VAS): the patient is instructed to mark
their ‘general state of health’ and ‘level of pain’ on two
100mm scales. The left end (0) corresponds to ‘very well’
and ‘no pain’ respectively, and the right end (100) to ‘ex-
tremely poor’ and ‘worst possible pain’ (100).
The HAQ assesses a patient’s level of functional ability.
There are 20 questions in 8 categories of functioning
that represent different activities - dressing, rising, eat-
ing, walking, hygiene, reach, grip and usual activities.
For each item there is a 4-level difficulty scale scored
from 0-3, representing no difficulty (0), some (1) or much
(2) difficulty, and unable to do (3). The highest component
score in each category determines the category score, un-
less the patient uses aids or devices for, or receives assist-
ance with activities in that category, in which case the
relevant category score is increased to 2 if the maximum
score was previously <2. The 8 category scores are aver-
aged into an overall score from zero to 3 [31].
The RAQoL consists of 30 statements derived directly
from relevant patients, using, as far as possible, their own
words. Respondents are required to indicate whether or
not each of the statements applies to them; each affirmedstatement contributes a score of 1 to the total score.
Scores can range from 0 to 30 with a [32].
The EQ5D is a generic measure, which provides a sin-
gle index value [33]. The scale includes a descriptive sys-
tem, comprising 5 questions relating to different aspects
of health each with 3 possible responses (‘no problems’,
‘some problems’ and ‘extreme problems’), and a visual
analogue scale capturing the patient’s self-rated health
where the endpoints are labelled ‘best imaginable health
state’ and ‘worst imaginable health state’.
The RA-WIS [34] consists of 23 statements about the
impact of the disease on working. Respondents are re-
quired to indicate whether or not each of the statements
applies to them; each affirmed statement contributes
with a score of 1 to the total score. Scores can range
from 0 to 23; a score less than 10 indicate low work in-
stability; scores in the range of 10-17 indicate moderate
work instability; scores above 17 indicate high risk of
work instability.
Duration of early morning stiffness; the patient is asked
to estimate the time that elapsed between awakening
and the time he/she is as flexible as he/she will be dur-
ing a day involving typical activities. Duration in minutes
is recorded up to a maximum of 720 min (12 h).Imaging assessments
MRI (high field gadolinium enhanced) of the dominant
hand and wrist (or alternative hand in the instance of
greater clinical evidence of synovitis at baseline) will be
performed at baseline, weeks 12, 24, 48 and 96. The
dominant hand will be scanned unless the alternative
hand has clinical evidence of greater synovitis at base-
line. This study will use MRI to assess erosions, synovitis
and bone marrow oedema using the accepted standard
of RA magnetic resonance imaging score (RAMRIS), as
well as direct synovial volume measurement and sensi-
tive dynamic contrast enhanced magnetic resonance im-
aging (DCE-MRI) for quantification of synovitis and
bone marrow oedema. Failure of MRI acquisition after
baseline will not constitute a protocol violation and will
not necessitate withdrawal from the study.
RAMRIS scoring system: scoring of erosions, synovitis
and bone marrow oedema, using the validated outcome
measures in RA clinical trials (OMERACT) system, will
be performed by 2 independent, experienced scorers.
The RAMRIS scoring system is a standardised, reliable,
validated scoring system for synovitis, erosion and
oedema. It has been successfully used to demonstrate re-
sponse to treatment, including bDMARD [35]. Direct
volume measurement of synovitis by manual segmenta-
tion will be performed. This will allow quantification of
low volumes of synovitis not differentiated by RAMRIS
scoring.
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(DCE)-MRI. Early enhancement rates measured from
DCE-MRI depend strongly on synovial vascularity and
capillary permeability and are therefore potentially better
markers of inflammatory activity than simple volume
measurements. DCE-MRI measurement of bone marrow
oedema will also be performed.
A blinded assessor will perform HRUS (Philips HDI
5000) of the same hand and wrist as chosen for MRI at
baseline, weeks 12, 24 and 48. If the target joint for syn-
ovial biopsy is at another site, the target joint will also
be scanned. Images will be assessed for synovitis, using
semi-quantitative scores of GS and PD and for presence
or absence of erosions.
Plain radiographs of bilateral hands (carpal, MCP and
PIP joints) will be performed at baseline, 12 and 24
months after the start of study medication to assess
structural damage. Radiographs will be scored as per the
modified Genant-modified Sharp scoring system [36].
Exploratory biosample based research
Blood samples will be collected at baseline and weeks
12, 24, 36, 48, 96, at time of early discontinuation (if in-
dicated) and at time of flare (if indicated). This will in-
clude collection of serum, plasma and heparinised blood
(for flow cytometry and functional studies).
Synovial biopsy (optional) will be taken from a target
joint: an active joint (identified at baseline by presence
of PD activity on ultrasound) or alternatively, if neces-
sary, a clinically uninvolved, accessible joint may be
chosen. The optional biopsy will be acquired via arthros-
copy or under ultrasound guidance at baseline and week
24; at week 48 in patients randomised to treatment arm
2 receiving delayed ETN from week 24, and at time of
flare in the case of loss of response in an initial re-
sponder. Failure of biopsy acquisition at any time point
will not constitute a protocol violation and will not ne-
cessitate withdrawal from the study.
The sample collection will be used for wide-ranging
studies including cellular phenotyping, soluble bio-
marker evaluation and gene expression studies.
A detailed study schedule is provided in Table 3.
Follow-up
At study completion (96 weeks), patients will be invited
to take part in the Inflammatory Arthritis Continuum
(IACON) study. This is an in-house, prospective, longi-
tudinal, observational study of patients with inflamma-
tory arthritis, with ethical approval to obtain blood
samples and clinical and imaging data in consenting pa-
tients. Inclusion of all patients with inflammatory arthritis
in IACON will allow recording of longer-term outcomes
such as sustained response and drug-free remission per-
mitting future observational work.Statistical considerations
Sample size
Clinical remission (DAS28 remission) forms the basis of
the primary outcome. The COMET study, reported remis-
sion rates in patients with very early RA (less than 4
months since diagnosis) treated with both ETN and MTX
or MTX monotherapy of 70 % versus 35 % respectively. In
patients with disease duration of less than 2 years but
greater than 4 months, treatment with ETN and MTX
was associated with 48 % remission rate. In the COMET
study patients in the very early RA group were recruited
within 4 months of RA diagnosis, using ACR 1987 criteria.
In contrast, VEDERA will recruit patients within 12
months of symptom onset. Whilst all patients will meet
RA criteria at the point of recruitment, ACR/EULAR
2010 criteria are being used, which identify patients at an
earlier stage of the disease course than the 1987 criteria,
and patients can potentially be recruited concurrently with
diagnosis. It is likely that patients recruited to VEDERA
will be at a similar stage in their disease course to the pa-
tients in the very early RA group in COMET, potentially
an even earlier stage.
To account for the possibility that the interval be-
tween the treatment groups may not be as large as
that seen in COMET a 30 % difference has been used
as a basis for the sample size calculation. Assuming
therefore that patients in treatment arm 1 are likely
to achieve up to 70 % remission, and treatment arm
2 approximately 40 % remission; for 80 % power at
the 5 % significance level and allowing for a 10 %
dropout rate, at least 49 patients per arm will be re-
quired. Increasing this to 60 per arm would allow for
a subgroup analysis of treatment arm 2 patients that
proceed to require delayed ETN and MTX to be
compared with treatment arm 1 and indeed those in
arm 2 that stay on conventional therapy. This is an
exploratory analysis; we estimate that 50 % of treat-
ment arm 2 patients will require delayed ETN and
MTX. With roughly 30 patients in each subgroup of
treatment arm 2 we will obtain sufficiently accurate
estimates of remission rates.
Analysis populations
The full analysis set will comprise all patients, allo-
cated to treatment groups as originally randomised,
irrespective of the treatment received and any subse-
quent deviations from the study protocol. The per
protocol set will comprise patients with primary end-
point data available, whose treatment complies with
the study protocol and for whom no other major
protocol violations are identified. Protocol violations
will be identified during a data review by the study
management team, blind to allocation, and prior to
locking the study database.
Table 3 Study schedule
Arm 2a Arm 2a Arm 2a
Study Week Weeks-4
to 0
Week 0 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Week 36 Week 48 Week 60 Week 72 Week 84 Week 96 Early
discontinuation
Study Phase Screen Baseline Safety
visit
10
Endpoint
End of
Study
Visit No. 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Informed Consent (patient
information will be provided
> 24 hrs prior to screen)
X
Inclusion/exclusion criteria X X
Randomisation X
Demographics, RA Hx, past
medical Hx, Family Hx, CV
risk factorsb
X
Physical examinationc X X X
Vital signsd X X X X X X X X X X X X
Pregnancy teste X X
ESR, CRP and HS-CRP X X X (Arm 2
only)
X X X X X X X X X X X X
Blood chemistry,
haematology
X X X X X X X X X X X X X X X
Urinalysis X X X X X X X X X
Serology: RF, ACPA and ANA X X X
ECG X
Chest x-ray/TB testf X
Hepatitis (B and C) serology X
VAS assessments: patient
general health, patient global,
patient pain
X X X (Arm 2
only)
X X X X X X X X X X X X
Physician VAS global disease
activity
X X X X X X X X
DAS28/44 joint assessment
g X X X (Arm 2
only)
X X X X X X X X X X X X
Early morning stiffness,
HAQ, RA QoL, EQ-5D, RA-WIS
X X X X X X X
a. Visits at weeks 8, 16 and 20 are only applicable to patients in treatment arm 2. b. Cardiovascular risk factors include: smoking habit (pack years), alcohol intake (units/week), amount of exercise taken, dietary intake
(days/week ≥ 5 portions fruit or vegetables consumed), and family history of premature cardiovascular disease age <55 years. c. Physical examination Includes height and body weight at screening. d. Blood pressure
after a 5-min rest, pulse rate and body temperature e. Urinary pregnancy test for women of child bearing potential only f. Chest x-ray, if not already performed within 24 weeks prior to the study. TB testing includes
TB Gold Quantiferon +/- T spot test +/- Mantoux test. g. Whenever possible, joint assessments should be performed by the same blinded assessor throughout the time course of the study to reduce potential
investigator bias
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Descriptive summary statistics will be provided for all
variables at baseline and at each visit at which the vari-
able is assessed. For continuous variables the following
information will be provided: number of patients (N),
mean, standard deviation, minimum, median, maximum
and 25 % and 75 % quartiles. For categorical data fre-
quency (absolute and relative) distributions will be pro-
vided. Differences between groups will be summarized
according to data type and 95 % confidence intervals
around these estimates will be constructed.
All inferential analyses will be conducted using two-
tailed tests at the 5 % level of significance. The Holm
correction (modified Bonferroni) will be employed on a
family-wise basis to control for multiple comparisons of
secondary outcomes.
Complete details of statistical analyses and methods,
including data handling conventions, will be contained
in a separate statistical analysis plan which will be final-
ized before the database is locked.
Primary efficacy analysis The primary efficacy analysis
will be conducted in the full analysis set. A Pearson’s
Chi-squared test will be used to compare the propor-
tions of subjects achieving clinical remission between
the two treatment arms. The 95 % confidence interval
for the odds of achieving clinical remission at week 48
will also be constructed. Analyses will be repeated in the
per protocol set.
Secondary efficacy analyses Secondary efficacy analyses
will be conducted in the full analysis set. Proportions
of patients achieving remission or other binary re-
sponses will be compared between groups using Pearson’s
Chi-squared tests. Changes in Gaussian-distributed con-
tinuous interval variables over time will be compared be-
tween groups using mixed between-within subjects
ANOVA; if the data do not meet the assumptions of the
test, approaches such as rank transformation will be used.
Time to event analyses will be conducted using log-rank
tests. Analyses will be repeated in the per protocol set.
Other planned analyses Immunological, gene expres-
sion and histological parameters will be compared be-
tween the two treatment arms using the same
approaches listed for the secondary analyses with ap-
propriate bioinformatics as indicated; subgroup ana-
lyses will repeat the between-arm comparison, split by
remission status (achieved/not achieved).
Clinical, imaging, synovial and immunological factors
associated with the odds of early and sustained remis-
sion will be investigated using univariable and multivari-
able binary logistic regression models.RAMRIS score is considered a secondary efficacy
outcome and will be analysed accordingly. For the
remaining exploratory imaging and biological end-
points, descriptive summaries will be provided for all
variables but inferential tests will not be performed.
Missing data For response variables (including the pri-
mary outcome) patients who discontinue study medica-
tion for lack of efficacy will be considered non-responders
from that point forward. In all other instances, missing
data will be addressed using multiple imputation. This
technique assumes the data are missing at random;
additional sensitivity analyses will include complete
case analysis, best case/worst case single imputation,
and imputation of a range of values to test the pos-
sible implications for the study conclusions if data are
missing not at random.
Ethical approval
Ethical approval was obtained from Leeds West Research
Ethics Committee (REC reference number: 10/H1307/138).
Discussion
This pragmatic, randomised phase IV, open-label study
is comparing first line ETN and MTX combination ther-
apy with a TT regimen starting with MTX monotherapy
regimen with sDMARD escalation followed by ETN and
MTX at week 24 if the treatment target of remission (or
LDA with physician impression of remission) is not
achieved.
The fundamental objective of this study is to deter-
mine whether TNFi instituted as first-line therapy in
early RA confers better outcomes (including depth of re-
mission and exploratory parameters indicating normal-
isation of immune system aberration) compared to a
conventional TT therapeutic approach with delayed
TNFi if required. The VEDERA study will contribute to
the existing evidence [37, 38] and in addition addresses
the question of whether quality of response to TNFi fol-
lowing MTX-failure differs from that achieved with first-
line use, prior to MTX exposure. The accurate imaging
aligned with the clinical assessments will also ensure
correct categorisation of patient response, to address the
weaknesses of clinical composite measures for assessing
remission [39].
Although the planned sample size (n=120) is relatively
small, the study is adequately powered to detect a clinic-
ally meaningful difference in remission rate, based on
existing published data. Secondary outcomes are ex-
pected to be correlated with the primary outcome and
we therefore anticipate the effect size to be similar for
these variables, which are considered supportive of the
primary hypothesis. For exploratory endpoints the focus
will be purely descriptive; the sample size has been
Dumitru et al. BMC Musculoskeletal Disorders  (2016) 17:61 Page 11 of 12inflated to help ensure that planned subgroup analyses
of patients receiving delayed ETN will include sufficient
patients, based on rules of thumb for pilot studies.
One of the secondary objectives of the study is remis-
sion maintenance and sustainability after ETN with-
drawal. There is increasing published data regarding this
[40], and while this study does not primarily seek to in-
vestigate drug tapering following remission, it will pro-
vide additional insights. Finally, the biosamples collected
will allow investigation of the pathobiology of disease,
mechanisms of drug action and predictors of response
and remission in order to enable more effective tailoring
of therapy in clinical practice.
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